Furthermore, it has been also reported that EGFR mediates NF-κB activation in most cancers cells and treatment with the EGFR tyrosine kinase inhibitor erlotinib or down-regulation of EGFR expression inactivated NF-κB, demonstrating that this pathway seems to be responsible for constitutive NF-κB activation in some cancers. The gene discussed is EGFR; the disease is cancer.